Lara Bischof
YOU?
Author Swipe
View article: Sex-associated differences in outcome of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation
Sex-associated differences in outcome of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation Open
View article: Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma Open
PET/CT plays an important role in staging of multiple myeloma (MM) and detecting extramedullary disease (EMD); however, its role in patients treated with commercially available CAR T cell therapies is unclear. We evaluated 61 patients trea…
View article: Impact of Evolving <scp>WHO</scp> and <scp>ICC</scp> Classifications on Prognosis and Outcomes in <scp>AML</scp> Patients Undergoing Allogeneic Stem Cell Transplantation
Impact of Evolving <span>WHO</span> and <span>ICC</span> Classifications on Prognosis and Outcomes in <span>AML</span> Patients Undergoing Allogeneic Stem Cell Transplantation Open
View article: Allogeneic stem cell transplantation for MDS—clinical issues, choosing preparative regimens and outcome
Allogeneic stem cell transplantation for MDS—clinical issues, choosing preparative regimens and outcome Open
Despite the vast heterogeneity of myelodysplastic neoplasm (MDS), treatment options are limited and an allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative approach. While, subsequently, allo-HSCT is the…
View article: Quantifying <i>NPM1</i> MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line?
Quantifying <i>NPM1</i> MRD in AML patients prior to allogeneic stem cell transplantation: Where to draw the line? Open
Today, assessment of measurable residual disease (MRD) increasingly allows a dynamic risk stratification and informs treatment decisions in acute myeloid leukemia (AML).1 For AML patients with NPM1 gene mutations quantitative PCR methods h…
View article: Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation
Prognostic impact of measurable residual clonal hematopoiesis in acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation Open
Graphical Abstract
View article: PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
PB2450: SEX-ASSOCIATED OUTCOME DIFFERENCES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) Open
Topic: 22. Stem cell transplantation - Clinical Background: Recent identifications of sex-associated differences in the biology of hematologic neoplasm highlights the need to explore sex as a so far underestimated factor influencing outcom…
View article: P508: THE PROGNOSTIC SIGNIFICANCE OF THE MEASURABLE RESIDUAL DISEASE STATUS WITHIN THE THREE AML ELN2022 RISK GROUPS
P508: THE PROGNOSTIC SIGNIFICANCE OF THE MEASURABLE RESIDUAL DISEASE STATUS WITHIN THE THREE AML ELN2022 RISK GROUPS Open
Background: The 2022 updated European LeukemiaNet (ELN) risk classification for acute myeloid leukemia (AML) includes risk adjustments during disease course by measurable residual disease (MRD) assessment. While the ELN2022 classification …
View article: P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION
P497: CLINICAL OUTCOMES OF NPM1-MUTATED ACUTE MYELOID LEUKEMIA (AML) PATIENTS WITH MEASURABLE RESIDUAL DISEASE (MRD) RELAPSE AFTER ACHIEVEMENT OF A FIRST MRD-NEGATIVE REMISSION Open
Background: Persisting MRD is a strong prognostic factor in NPM1-mutated (mut) AML patients (pts) and a new risk factor according to the European LeukemiaNet (ELN) 2022 classification. Data on MRD relapse in morphologic complete remission …
View article: Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation
Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation Open
Although the presence of FLT3-ITD, as well as levels of the FLT3-ITD allelic ratio, have been described as prognostic factors in acute myeloid leukemia (AML), little is known about how the FLT3-ITD allelic ratio impacts patients’ outcomes …
View article: Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation Open
View article: A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older
A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older Open
View article: Outcome prediction by the knowledge bank approach in <scp>acute myeloid leukemia</scp> patients undergoing allogeneic stem cell transplantation
Outcome prediction by the knowledge bank approach in <span>acute myeloid leukemia</span> patients undergoing allogeneic stem cell transplantation Open
Acute myeloid leukemia (AML) is a disease resulting from different molecular aberrations which give rise to heterogeneous biological characteristics and patient outcomes.1 Most patients are older than 60 years at diagnosis and often presen…
View article: P509: CLONAL HEMATOPOIESIS-ASSOCIATED MUTATIONS AS MEASURABLE RESIDUAL DISEASE MARKERS IN ACUTE MYELOID LEUKEMIA PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION
P509: CLONAL HEMATOPOIESIS-ASSOCIATED MUTATIONS AS MEASURABLE RESIDUAL DISEASE MARKERS IN ACUTE MYELOID LEUKEMIA PATIENTS FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION Open
Background: Clonal hematopoiesis (CH)-associated mutations (mut) are frequent in acute myeloid leukemia (AML), appear early in leukemogenesis, and often persist in remission after chemotherapy. Following allogeneic hematopoietic stem cell …
View article: P1356: PATIENT-SPECIFIC DIGITAL DROPLET PCR ASSAYS FOR MINIMAL RESIDUAL DISEASE DETECTION OF RUNX1 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION
P1356: PATIENT-SPECIFIC DIGITAL DROPLET PCR ASSAYS FOR MINIMAL RESIDUAL DISEASE DETECTION OF RUNX1 MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION Open
Background: The persistence of non-clonal-hematopoiesis mutations (mut) in remission prior to a consolidating allogeneic stem cell transplantation (HSCT) in acute myeloid leukemia (AML) patients (pts) has been associated with a higher rela…
View article: Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission
Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission Open
Allogeneic hematopoietic stem cell transplantation (HSCT) offers the best chance for relapse-free survival to most patients with acute myeloid leukemia (AML). It may be performed during complete remission or delayed until after the first r…
View article: Impact of<i>IDH1</i>and<i>IDH2</i>mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation
Impact of<i>IDH1</i>and<i>IDH2</i>mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation Open
Somatic mutations in the isocitrate dehydrogenase 1 and 2 genes (IDH1 and IDH2) are common in acute myeloid leukemia (AML). The prognostic impact of the presence of IDH mutations may be influenced by the comutational status, the specific l…
View article: Combining 3D-Printing and Electrospinning to Manufacture Biomimetic Heart Valve Leaflets
Combining 3D-Printing and Electrospinning to Manufacture Biomimetic Heart Valve Leaflets Open
Electrospinning has become a widely used technique in cardiovascular tissue engineering as it offers the possibility to create (micro-)fibrous scaffolds with adjustable properties. The aim of this study was to create multilayered scaffolds…
View article: Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Open
Background: For most patients with acute myeloid leukemia (AML) harboring a trisomy 8 an allogeneic hematopoietic stem cell transplantation (HSCT) is a suitable and recommended consolidation therapy. However, comparative outcome analyses b…